Shedding light on the epidemiology of gastroesophageal reflux disease in India—a big step forward

Gaddam, Srinivas

doi:10.1007/s12664-011-0108-6

Cited by 11 publications

(6 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…3,4 However, in Asia, GORD prevalence has been found to be as low as 2.3%, whereas a study conducted in India estimated the prevalence of GORD to be 16-18%, which is analogous to Western countries. 5,6 Limited studies have been conducted on the prevalence of GORD in Africa, although a Nigerian study estimated the prevalence of GORD to be 23%. 7,8 GORD has proven to have a substantial burden on public health strategies as its treatment is costly and symptoms can affect the quality of life of patients.…”

Section: Introductionmentioning

confidence: 99%

“…In Western countries, the prevalence of GORD and its associated symptoms is 10–20% . However, in Asia, GORD prevalence has been found to be as low as 2.3%, whereas a study conducted in India estimated the prevalence of GORD to be 16–18%, which is analogous to Western countries . Limited studies have been conducted on the prevalence of GORD in Africa, although a Nigerian study estimated the prevalence of GORD to be 23% …”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Raft‐forming polysaccharides for the treatment of gastroesophageal reflux disease (GORD): Systematic review

Yousaf

Nirwan

Smith

et al. 2019

J of Applied Polymer Sci

View full text Add to dashboard Cite

Gastroesophageal reflux disease (GORD) is a common condition induced by unwarranted reflux of gastric and duodenal contents into the esophagus, and insufficient clearance of refluxate from it. Pharmaceutical formulations possessing raft‐forming capability offers an excellent alternative to conventional treatment options to treat uncomplicated GORD. These formulations typically contain a polymer, which performs distinctively upon contact with gastric acid and develops a foam‐like structure that can float on gastric contents. This review aims to feature research articles and patents that cover this topic. After undergoing a standardized literature search following preferred reporting items for systematic reviews and meta‐analyses guidelines, we have included 38 research articles and 18 patents describing the role of raft‐forming polymers in the treatment of GORD. This is a comprehensive review of formulation/testing of raft‐forming polymers. As expected, the majority of the studies focused on alginate; however, fewer studies have reported the use of pectin, xanthan gum, and raw psyllium fibers (husk). Moreover, it can be concluded from this comprehensive systematic review that a detailed characterization of raft‐forming formulations, type, and concentration of used active and inactive materials and different formulations factors are essential for the development of successful anti‐reflux raft‐forming formulations. © 2019 Wiley Periodicals, Inc. J. Appl. Polym. Sci. 2019, 136, 48012.

show abstract

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Raft‐forming polysaccharides for the treatment of gastroesophageal reflux disease (GORD): Systematic review

Yousaf

Nirwan

Smith

et al. 2019

J of Applied Polymer Sci

View full text Add to dashboard Cite

show abstract

“…9 GERD affects quality of life of patients, reduces their functional activity, increases the economic burden and predisposes them to more serious conditions as in Barrett esophagus and esophageal adenocarcinoma which is difficult to treat eventually. [10][11][12][13] There are many factors whichare thought to be associated with GERD symptoms, including dietary factors, alcohol consumption, smoking, the intake of NSAIDs and sleeping position. 14 Various studies indicate that increased body mass index (BMI) is also a risk factor for GERD.…”

Section: Introductionmentioning

confidence: 99%

Gastroesophageal Reflux Disease: Prevalence and ItsRisk Factors in Rural Bangladesh

Ghosh

Nath

Ghosh

et al. 2018

Bangladesh Med Res Counc Bull

View full text Add to dashboard Cite

Gastroesophageal Reflux Disease (GERD) is a global disease, and evidence suggests that its prevalence is increasing. Prevalence estimates show considerable geographic variation. According to WHO, prevalence of GERD in far East Asia currently consistently lower than 10%, which is 8-20% in India. No such population based data are available in Bangladesh. Thus, the study was designed to determine the prevalence of GERD and its risk factors in rural community of Bangladesh. This descriptive, cross-sectional study was carried out during January to June 2015 by using a validated questionnaire through door to door interview among randomly selected 2000 participants in a rural community of Bangladesh. A cutoff point 3 was chosen as a valid and reliable scale to confirm GERD. Among the study participants, 1212 were male and 788 were female. Their average age range was 18 to 60 years. A total of 136 participants were found to have GERD symptoms and among them 43 were men and 93 were women. Thus, the prevalence of GERD in the study was 6.8%. GERD was highly associated with higher age group, women, Muslims, and participants with diabetes mellitus, asthma and overweight. Prevalence of GERD in rural community of Bangladesh is lower than that of the western world. For a better understanding on GERD, it is important that a study should be carried in a representative samples across Bangladesh.

show abstract

“…Currently, therapy is essentially aimed at decreasing gastric acid and the most common drugs used are H 2 antagonists and proton pump inhibitors (PPIs). 4,5 Currently, PPIs (omeprazole, lansoprazole, pantoprazole, rabeprazole and esomeprazole) are widely used for the treatment of APDs and have short half-lives which range from 1 to 1.5 hours. All 5 PPIs are effective and safe; however, there are differences in PPI pharmacokinetic and pharmacodynamics profiles that might influence their clinical utility.…”

Section: Introductionmentioning

confidence: 99%

Prescribing pattern of proton pump inhibitors in the management of acid peptic disorders, focus on ilaprazole

Mayabhate

2016

Int J Basic Clin Pharmacol

View full text Add to dashboard Cite

INTRODUCTIONAcid peptic disorders (APDs) are a collective term that includes many conditions such as peptic ulcer disease, GERD and Gastritis. Acid peptic disorders are the result of distinctive, but overlapping pathogenic mechanisms leading to either excessive acid secretion or diminished mucosal defense. The prevalence of gastroesophageal reflux disease (GERD) in India is likely to be between 8% and 19%, which is comparable to GERD prevalence rates published in western countries.2 Peptic ulcer disease (PUD) tends to have a chronic remitting course with imperfect correlation between symptoms and the presence of an ulcer. Each year PUD affects 4 million people around the world. A recent study by Dutta AK et al showed a time trends in epidemiology of peptic ulcer disease in India and observed the frequencies of 2.9% for duodenal ulcer and 2.7% gastric ulcer from 1988 to 2008. The causes of APD include H. Pylori infection, over use of NSAIDS, smoking and alcohol consumption and it is also linked with stress and dietary factors such as spicy and oily food. The increase in incidence of APD in the current scenario can be linked to the present stressful lifestyles. Patients commonly present with nausea, heartburn, dysphagia and abdominal pain. If left ABSTRACT Background: Acid peptic disorders (APDs) result from characteristic but overlapping pathogenic mechanisms that involve acid effects on diminished mucosal defense. Proton pump inhibitors (PPIs) have become a mainstay in the APDs. This survey was aimed to determine the usage profile of different proton pump inhibitors and overall physicians' opinion about the clinical experience with newer PPI, ilaprazole. Methods: This survey was based on the clinical experience of 107 randomly selected physicians on an aggregate patient basis in the management of acidpeptic disorders from different parts of India. A data report form (DRF) comprising of various questions was answered by these physicians. The responding physicians answered the DRF of patients who suffered from acidpeptic disorders and were eligible for PPI therapy. A minimum of 50 patients per physician were evaluated in this survey. Results: The commonly encountered APD in physicians' clinical practice were gastroesophageal reflux disorder (GERD) followed by non-ulcer disease. 58.88% physicians highlighted the prevalence of night time symptoms of APD reported by the patients. About 1/4th physicians were of the opinion that longacting PPIs would be the preferred to offer 24 hour control of gastric acid secretion thereby controlling the nocturnal symptoms. 63.73% of physicians reported significantly better symptomatic relief with once daily dose of ilaprazole than existing PPIs. Conclusions: This survey highlights the lack of 24 hour acid control in APDs with use of conventional PPIs leading to variety of symptoms, especially at night, seriously hampering the sleep quality. Ilaprazole displays important advantages in the clinical settings, with regard to better probability of extending the inhibition of acid secret...

show abstract

Shedding light on the epidemiology of gastroesophageal reflux disease in India—a big step forward

Cited by 11 publications

References 18 publications

Raft‐forming polysaccharides for the treatment of gastroesophageal reflux disease (GORD): Systematic review

Raft‐forming polysaccharides for the treatment of gastroesophageal reflux disease (GORD): Systematic review

Gastroesophageal Reflux Disease: Prevalence and ItsRisk Factors in Rural Bangladesh

Prescribing pattern of proton pump inhibitors in the management of acid peptic disorders, focus on ilaprazole

Contact Info

Product

Resources

About